Genmab A (GMAB) Non-Current Debt (2019 - 2026)
Genmab A (GMAB) posted Non-Current Debt of $4.9 billion for Q1 2026, down 1.36% on a QoQ basis from $5.0 billion in Q4 2025, and up 3724.03% year-over-year from $129.0 million in Q1 2025.
Genmab A (GMAB) Non-Current Debt (2019 - 2026) Analysis & Trends
Genmab A's Non-Current Debt history runs 4 years deep, the most recent figure standing at $4.9 billion for Q1 2026.
- Quarterly Non-Current Debt rose 3724.03% year-over-year to $4.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 3724.03% YoY) and the FY2025 annual result came in at $5.0 billion, changed N/A from the prior year.
- Non-Current Debt was $4.9 billion for Q1 2026 at Genmab A, down from $5.0 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $5.0 billion in Q4 2025 and bottomed at $129.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 4.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.93 Bn |
| Dec 31, 2025 | 5.00 Bn |
| Mar 31, 2025 | 129.00 Mn |
| Sep 30, 2020 | 295.00 Mn |
| Dec 31, 2019 | 155.00 Mn |
| Sep 30, 2019 | 157.61 Mn |